Are Your CERs Audit Ready? 10 Warning Signs Before Your Next Notified Body Review

Notified Body review under the European Union Medical Device Regulation (EU MDR) comes with increased scrutiny of the Clinical Evaluation Report (CER). Even well-prepared manufacturers can encounter unexpected questions that delay approvals or trigger additional review cycles. Often, these observations do not stem from a lack of clinical data, but rather from subtle gaps in documentation, traceability, or consistency across the technical file.

A CER is far more than a regulatory submission document. It is the cornerstone of demonstrating your medical device’s clinical safety, performance, and benefit-risk profile throughout its lifecycle. To comply with Article 61 and Annex XIV, Part A, of the EU MDR, manufacturers must continuously update a clinical evaluation based on robust evidence. Notified body reviewers expect CERs to align seamlessly with broader technical documentation under Annex II and Annex III.

Addressing documentation gaps proactively helps manufacturers minimize regulatory delays, reduce costly rework, and approach notified body reviews with absolute confidence.

Warning Signs in Your CER

If your CER has one or more of these gaps, it may benefit from a comprehensive review before your next conformity assessment or surveillance audit:

1. Clinical evidence has not been updated to reflect current data or current clinical practice.
2. Literature search protocol and results are not systematic, comprehensive, reproducible, or adequately documented.
3. Clinical benefits from the device are not stated or not appropriately defined as required by the EU MDR.
4. Clinical claims are not fully supported by objective clinical evidence on your device.
5. The benefit-risk conclusion lacks supporting evidence and scientific justification.
6. Post-Market Surveillance (PMS) and Post-Market Clinical Follow-up (PMCF) findings are not effectively integrated into the evaluation.
7. Device equivalence is inadequately justified or no longer acceptable under MDR expectations.
8. Risks in the CER, risk management, and Instructions for Use (IFU) are not fully aligned.
9. The CER conclusions do not fully demonstrate conformity to the General Safety and Performance Requirements (GSPRs).
10. The report does not adequately reflect evolving regulatory expectations, for example, the MDCG guidance documents.

While every issue deserves attention, these deficiencies account for a significant proportion of non-conformities in notified body clinical reviews.

Key Areas of Focus

1. Clinical Evidence StrategyA CER should demonstrate not only that clinical evidence exists, but also why it is relevant, sufficient, current, and appropriate for the intended use, indications, target patient population, and adequately support claims. Reliance on legacy literature, limited datasets, or outdated evidence can inadvertently undermine an otherwise sound evaluation. A gap assessment helps clarify whether additional published literature, PMS findings, or PMCF activities are needed prior to submission, or identify the need to present the available evidence in a structured format expected by the reviewer.
2. Alignment Across Technical DocumentationNotified bodies evaluate the CER alongside risk management files, PMS reports, PMCF evaluations, IFUs, and other parts of the technical documentation. Discrepancies in the definition of intended use, indications, or intended populations, risks, or clinical evidence can trigger waves of questions and prolong the review cycle. Often, CERs get rejected for entirely avoidable reasons, such as mismatch in the intended use verbiage, lack of measurable safety and performance objectives, or clinical evidence that was not coherently presented or adequately justified.
3. State of the ArtThe state-of-the-art section should extend beyond a static summary of published literature. It must provide a clear, relevant overview of current clinical practice, available treatment options, applicable standards, and how your device compares within its intended clinical context. A clinical evaluation not based on measurable benchmarks from the State of the Art is unlikely to pass notified body scrutiny.
4. Methodology and TraceabilityReviewers expect clarity so that they can trace every major conclusion back to supporting clinical evidence, risk management documentation, and applicable GSPRs without ambiguity. Transparency in literature search strategies, inclusion/exclusion criteria, and critical appraisal methods builds immediate trust with the reviewer and facilitates a much smoother assessment. Reference to the relevant MDCG guidance documents strengthens their confidence in the scientific validity of the level of evidence in the clinical evaluation.

Why Conduct a CER Readiness Review?

Preparing for a notified body review should begin well before submission. An independent CER readiness assessment enables your team to identify documentation gaps while there is still time to address them efficiently, minimizing stress and safeguarding product timelines.

A proactive review can:

• Identify potential audit findings proactively.
• Ensure consistency across the CER and risk management documents, PMS, PMCF, and IFUs.
• Reduce avoidable deficiency letters and repeated review cycles.
• Support predictable costs and time-to-compliance/time-to-market.
• Strengthen internal confidence ahead of notified body audits.

Strengthening CER Quality Through Early Expert Review

As the clinical evidence expectations under MDR continue to evolve, the need for robust clinical evaluations that are scientifically justified, evidence-based, and fully traceable is undeniable. Collaborating with a regulatory partner for an independent review provides an objective assessment of your CER and strong action plan for the identified gaps in clinical evidence and PMCF strategy. While the various departments within manufacturing organizations may be focussed on specific processes and activities, clinical and regulatory subject matter experts with extensive experience of clinical evaluation and the notified body clinical review process can provide practical recommendations and support you in the action plan to address the non-conformities.

Whether you are preparing a new CER, updating an existing report, or planning for a surveillance audit, investing in CER readiness today can help prevent costly observations tomorrow. A proactive, structured approach not only supports regulatory compliance but also demonstrates a sustained commitment to patient safety, product performance, and regulatory excellence.

Is Your CER Ready for Notified Body Scrutiny?

Even small gaps in clinical evidence, traceability, or document alignment can result in avoidable questions, deficiency letters, and extended review timelines. An independent CER readiness assessment helps identify potential findings before submission and provides a clear roadmap for remediation.

Celegence’s clinical and regulatory experts support manufacturers with:

• CER gap assessments and readiness reviews
• Clinical evidence strategy development
• Literature review and appraisal
• State-of-the-art evaluations
• CER remediation and updates
• PMCF and PMS integration
• Traceability to GSPRs and risk management documentation
• Support during Notified Body interactions

Preparing for an MDR submission, surveillance audit, or CER update?

Connect with our experts to assess your CER readiness and strengthen your clinical evidence strategy.

For information, reach out to us at info@celegence.com or contact us online at celegence.com